DUBLIN--(BUSINESS WIRE)--The "Neuroendocrine Tumors (NETs) - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.
The market of Neuroendocrine Tumors in 7MM was found to be USD 3.45 billion in 2016.
Neuroendocrine Tumors (NETs) - Market Insights, Epidemiology and Market Forecast-2027 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of NETs in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, current and forecasted market size of Neuroendocrine Tumors from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
This segment of the NETs report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Detailed chapter for upcoming therapies like Azedra (Progenics Pharmaceuticals), 177Lu-edotreotide PRRT (ITM Isotopen Technologien Muenchen), Sulfatinib (Hutchison MediPharma), Axitinib (Pfizer), RRx-001 (EpicentRx), Entrectinib (Ignyta), AMG-479 (Amgen), Carfilzomib (Amgen), ATG-008 (Antengene) and Fosbretabulin (Mateon Therapeutics) have been covered in the report.
Key Topics Covered:
1. Key Insights
2. Neuroendocrine Tumors Epidemiology Overview at a Glance
3. Disease Background and Overview: Neuroendocrine Tumors (NET)
4. Epidemiology and Patient Population
5. Treatment Algorithm
6. Unmet needs
7. Marketed drugs
8. Emerging drugs
9. Key Cross Competition
10. Neuroendocrine Tumors: 7 Major Market Analysis
11. Market Drivers
12. Market Barriers
13. Appendix
Companies Mentioned
- Novartis
- Pfizer
- Ipsen Biopharmaceuticals Inc.
- Advanced Accelerator Applications S.A.
- Progenics Pharmaceuticals
- ITM Isotopen Technologien Muenchen
- Amge
- Advenchen Laboratories
- Antengene
- Ignyta
- Mateon Therapeutics
- Bristol-Myers Squibb
- Novar
- Merck
- EpicentRx
- Pfizer
- Exelixis
- Camurus
- Genentech
- Eisai
- Teclison
- Tarveda Therapeutics
- Hutchison MediPharma
- Pharmacyclics
- Eli Lilly
- Altor Biosciences
- Trio Medicines
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/zxbcls/global?w=4
